Susceptibilities of Mycoplasma hominis, M. pneumoniae , and Ureaplasma urealyticum to GAR-936, Dalfopristin, Dirithromycin, Evernimicin, Gatifloxacin, Linezolid, Moxifloxacin, Quinupristin-Dalfopristin, and Telithromycin Compared to Their Susceptibilities to Reference Macrolides, Tetracyclines, and Quinolones
Open Access
- 1 September 2001
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (9) , 2604-2608
- https://doi.org/10.1128/aac.45.9.2604-2608.2001
Abstract
The susceptibilities of Mycoplasma hominis , Mycoplasma pneumoniae , and Ureaplasma urealyticum to eight new antimicrobial agents were determined by agar dilution. M. pneumoniae was susceptible to the new glycylcycline GAR-936 at 0.12 μg/ml and evernimicin at 4 μg/ml, but it was resistant to linezolid. It was most susceptible to dirithromycin, quinupristin-dalfopristin, telithromycin, reference macrolides, and josamycin. M. hominis was susceptible to linezolid, evernimicin, and GAR-936. It was resistant to macrolides and the ketolide telithromycin but susceptible to quinupristin-dalfopristin and josamycin. U. urealyticum was susceptible to evernimicin (8 to 16 μg/ml) and resistant to linezolid. It was less susceptible to GAR-936 (4.0 μg/ml) than to tetracycline (0.5 μg/ml). Telithromycin and quinupristin-dalfopristin were the most active agents against ureaplasmas (0.06 μg/ml). The new quinolone gatifloxacin was active against M. pneumoniae and M. hominis at 0.12 to 0.25 μg/ml and active against ureaplasmas at 1.0 μg/ml. The MICs of macrolides were markedly affected by pH, with an 8- to 32-fold increase in the susceptibility of M. pneumoniae as the pH increased from 6.9 to 7.8. A similar increase in susceptibility with increasing pH was also observed with ureaplasmas. Tetracyclines showed a fourfold increase of activity as the pH decreased 1 U, whereas GAR-936 showed a fourfold decrease in activity with a decrease in pH.Keywords
This publication has 30 references indexed in Scilit:
- Comparative Activities of Telithromycin (HMR 3647), Levofloxacin, and Other Antimicrobial Agents against Human MycoplasmasAntimicrobial Agents and Chemotherapy, 2000
- Comparative Susceptibilities of Various Aids-Associated and Human Urogenital Tract Mycoplasmas and Strains of Mycoplasma Pneumoniae to 10 Classes of Antimicrobial Agent In VitroJournal of Medical Microbiology, 1998
- In vitro activity of dirithromycin, a new macrolide antibiotic, against Mycoplasma speciesDiagnostic Microbiology and Infectious Disease, 1994
- Effect of pH, Inoculum Size, and Incubation Time on the Susceptibility of Ureaplasma urealyticum to Erythromycin In VitroClinical Infectious Diseases, 1993
- Effects of environmental factors on the in vitro potency of azithromycinEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin againstMycoplasma pneumoniae, Mycoplasma hominis andUreaplasma urealyticumEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990
- Resistance of Mycoplasma pneumoniae to macrolides, lincomycin and streptogramin BJournal of Antimicrobial Chemotherapy, 1986
- Human Respiratory Tract Infections with Mycoplasmas and Their in vitro Susceptibility to Tetracyclines and Some Other AntibioticsChemotherapy, 1975
- Resistance of Mycoplasma pneumoniae to erythromycin and other antibioticsThe Journal of Pediatrics, 1970
- SUSCEPTIBILITY OF MYCOPLASMA PNEUMONIAE TO 21 ANTIBIOTICS IN VITRO*The Lancet Healthy Longevity, 1967